Decision: Favourable
Study Title:
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
NREC Code:
21-NREC-CT-021
Decision:
Favourable
Meeting Date:
21/07/2021
Study Type:
CT application
Principal Investigator:
Prof Douglas Veale
PI Institution:
St Vincent's University Hospital
Sponsor:
Bristol Myers Squibb International Corporation